Up next
Share article
The post has been shared by 0 people.
Mail 0
LinkedIn 0
Twitter 0

DCAT Week ’18: CDMOs, CMOs, and Suppliers: Expansion Roundups

What have been the key developments from contract development and manufacturing organizations (CDMOs), contract manufacturing organizations (CMOs), and other suppliers and companies supporting pharmaceutical /biopharmaceutical development and manufacturing thus far in 2018?

This special issue of DCAT Value Chain Insights highlights key developments from January 2018 to April 3, 2018 of DCAT member companies making the news. 

Chemical/Chemical API Manufacturing

Biologics Manufacturing

Formulation/Drug Product Manufacturing

Packaging

General

 

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent Feature Articles

Blockbuster Potential: Which New Contenders Launching in 2024 Lead the Pack?

By
What are the blockbusters of the future? A recent industry analysis points to the leading contenders from late-stage or newly approved drugs that are slated to launch in 2024 and that are poised for potential blockbuster status over the next five years. Which drugs are the leading contenders?

EU Launches Critical Medicines Alliance; Is New Legislation on Mfg & Supply Chain Next?

By
The European Commission launched late last month, the Critical Medicines Alliance, a consultative mechanism for policymakers to address drug shortages and assure the supply of critical medicines in the EU. Does it portend potential legislation incentivizing manufacturing & supply-chain resilience?

The Battle of the Blockbusters: GLP-1 Agonists

By
GLP-1 agonist drugs, in the form of Novo Nordisk’s Wegvoy/Ozempic, and Lilly’s Mounjaro for weight management and treating Type II diabetes, were blockbuster winners in 2023, putting this therapeutic sector into high focus. What has been the impact on manufacturing and what are other contenders in this high-growth sector?

Manufacturing & Supply Lines: Small-Molecule APIs

By
Small-molecule drugs still dominate new drug approvals, as measured by the number of new molecular entities approved by the FDA’s Center for Drug Evaluation and Research, but are they translating into market success? DCAT Value Chain Insights takes a look on the market for drugs with small-molecule active pharmaceutical ingredients and related supply–demand fundamentals.